Innate Immunotherapeutics Limited announced on completed the acquisition of Amplia Therapeutics Pty Ltd. (Amplia). As a result of the transaction, the company will accelerate the development of Amplia's Focal Adhesion Kinase (FAK) inhibiting drug candidates for application in immuno-oncology and other indications. The company announced that Elizabeth Hopkins, Andrew Sneddon, and Chairman Michael Quinn, all of whom are, on 4 May 2018 stepping down from the Board. Joining the Board's remaining members Robert Peach and Simon Wilkinson from 4 May 2018 are Andrew Cooke, Chris Behrenbruch, Chris Burns, and Warwick Tong. Mr. Cooke. Mr. Cooke will chair the company's Audit Committee. Behrenbruch, Burns, and Tong were formally directors of Amplia and have a deep knowledge of the FAK assets now owned by Innate. Each also has over 20 years hands-on experience in the pharmaceutical and biotechnology industry. Chris is currently CEO of Telix Pharmaceuticals Limited and a non-executive director of Factor Therapeutics. In addition to Warwick Tong current role as CEO and Director of CTx he is a member of the Governance Board of the ARC CoE in Convergent Bio Nano Science, a member of the SAB of the Maurice Wilkins Centre in Auckland NZ, the Advisory Board of Cortex Health, Melbourne and a member of the Industry Advisory Board, School of Biomedical Sciences, University of Melbourne. Most recently Christopher Burns was a Laboratory Head at the Walter and Eliza Hall Institute of Medical Research in Melbourne and is now CEO and Research Director at MetabloQ Pharmaceuticals.